EP
VIR icon

Eversept Partners’s Vir Biotechnology VIR Stock Holding History

Eversept Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Sell
156,636
-93,364
-37% -$888K 0.08% 97
2026
Q1 		$2.24M Buy
+250,000
New +$1.99M 0.12% 85

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Eversept Partners's VIR Position: Q2 2026 in Review

Eversept Partners reduced its Vir Biotechnology (VIR) stake by 37% in Q2 2026, selling an estimated $888K and leaving 156,636 shares worth $1.6M. The position accounts for 0.08% of the portfolio, ranked #97.

Eversept Partners first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.24M in Q1 2026. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Eversept Partners held 156,636 shares of Vir Biotechnology worth $1.6M as of Q2 2026.
  • Eversept Partners sold 93,364 Vir Biotechnology shares in Q2 2026, an estimated $888K.
  • Vir Biotechnology made up 0.08% of Eversept Partners's portfolio in Q2 2026, its #97 holding.
  • Eversept Partners first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • Eversept Partners's Vir Biotechnology position peaked at $2.24M in Q1 2026.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.